Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism

BMC Cancer

Hans F Schoellhammer²  Felicia Hsu²  Courtney Vito²  Peiguo Chu³  Jinha Park¹  James Waisman⁴  Joseph Kim² 

[1] Department of Radiology, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Rd., Duarte, CA 91010, USA

[2] Division of Surgical Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, MD, 1500 E. Duarte Rd., Duarte, CA 91010, USA

[3] Department of Pathology, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Rd., Duarte, CA 91010, USA

[4] Department of Medical Oncology and Experimental Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Rd., Duarte, CA 91010, USA

关键词: Complete pathologic response;    Pertuzumab;    Trastuzumab;    Breast cancer liver metastases;    Targeted therapy;    HER2-positive breast cancer;   

Others  :  858915
DOI  :  10.1186/1471-2407-14-242

 received in 2013-11-14, accepted in 2014-03-10,  发布年份 2014

【 摘 要 】

Background

Although breast cancer frequently metastasizes to the bones and brain, rarely breast cancer patients may develop isolated liver metastasis. There is increasing data that anti-HER2 targeted therapy in conjunction with systemic chemotherapy may lead to increased rates of pathologic complete response in the primary breast cancer. However, little is known about its effects on metastatic liver disease.

Case presentation

We report the treatment of a 54-year-old female who was diagnosed with HER2-positive invasive ductal carcinoma and synchronous breast cancer liver metastasis (BCLM). The patient underwent eight cycles of standard docetaxel with two anti-HER2 targeted agents, trastuzumab and pertuzumab. Subsequent radiographic imaging demonstrated complete radiographic response in the primary lesion with an approximate 75% decrease in the liver metastasis. After informed consent the patient underwent modified radical mastectomy that revealed pathologic complete response. Re-staging demonstrated no new disease outside the liver and a left hepatectomy was performed for resection of BCLM. Final pathologic examination revealed no residual malignant cells in the liver specimen, indicating pathologic complete response. Herein, we discuss the anti-HER2 targeted agents trastuzumab and pertuzumab and review the data on dual HER2 antagonism for HER2-positive breast cancer and the role of surgical resection of BCLM.

Conclusions

The role of targeted agents for metastatic HER2-positive breast cancer is under active clinical trial investigation and we await the maturation of trial results and long-term survival data. Our results suggest that these agents may also be effective for producing considerable pathologic response in patients with BCLM.

【 授权许可】

   
2014 Schoellhammer et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England J Med 2001, 344(11):783-792.
• [2]Babiera GV, Rao R, Feng L, Meric-Bernstam F, Kuerer HM, Singletary SE, Hunt KK, Ross MI, Gwyn KM, Feig BW, Ames FC, Hortobagyi GN: Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 2006, 13(6):776-782.
• [3]Rapiti E, Verkooijen HM, Vlastos G, Fioretta G, Neyroud-Caspar I, Sappino AP, Chappuis PO, Bouchardy C: Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006, 24(18):2743-2749.
• [4]Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R, et al.: Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013, 11(7):753-760.
• [5]GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet] http://globocan.iarc.fr webcite
• [6]Rosa Mendoza ES, Moreno E, Caguioa PB: Predictors of early distant metastasis in women with breast cancer. J Cancer Res Clin Oncol 2013, 139(4):645-652.
• [7]Dittmar Y, Altendorf-Hofmann A, Schule S, Ardelt M, Dirsch O, Runnebaum IB, Settmacher U: Liver resection in selected patients with metastatic breast cancer: a single-centre analysis and review of literature. J Cancer Res Clin Oncol 2013, 139(8):1317-1325.
• [8]Selzner M, Morse MA, Vredenburgh JJ, Meyers WC, Clavien PA: Liver metastases from breast cancer: long-term survival after curative resection. Surgery 2000, 127(4):383-389.
• [9]Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14(4):320-368.
• [10]Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R, Herceptin Adjuvant (HERA) Trial Study Team: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011, 12(3):236-244.
• [11]Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England J Med 2005, 353(16):1673-1684.
• [12]Capelan M, Pugliano L, De Azambuja E, Bozovic I, Saini KS, Sotiriou C, Loi S, Piccart-Gebhart MJ: Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol 2013, 24(2):273-282.
• [13]Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, CLEOPATRA Study Group: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. New England J Med 2012, 366(2):109-119.
• [14]Zardavas D, Bozovic-Spasojevic I, de Azambuja E: Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer. Curr Opin Oncol 2012, 24(6):612-622.
• [15]Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M: Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009, 69(24):9330-9336.
• [16]Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010, 28(7):1138-1144.
• [17]Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13(1):25-32.
• [18]Elias D, Lasser P, Spielmann M, May-Levin F, el Malt O, Thomas H, Mouriesse H: Surgical and chemotherapeutic treatment of hepatic metastases from carcinoma of the breast. Surg Gynecol Obstet 1991, 172(6):461-464.
• [19]Elias D, Lasser PH, Montrucolli D, Bonvallot S, Spielmann M: Hepatectomy for liver metastases from breast cancer. Eur J Surg Oncol 1995, 21(5):510-513.
• [20]Foster JH: Survival after liver resection for secondary tumors. Am J Surg 1978, 135(3):389-394.
• [21]Polistina F, Costantin G, Febbraro A, Robusto E, Ambrosino G: Aggressive treatment for hepatic metastases from breast cancer: results from a single center. World J Surg 2013, 37(6):1322-1332.